PR in the Philippines

HIGHLIGHTS:- The Group’s gross billings amounted to approximately RMB1,705.4 million, representing an increase of approximately 83.3% from approximately RMB930.5 million for the Corresponding Period.- The Group’s total revenue was approximately RMB2,099.7 million, representing an increase of approximately 133.8% from approximately RMB898.1 million for the Corresponding Period.- The profit attributable to Shareholders of the Group was approximately RMB865.4 million, as compared to the net loss attributable to Shareholders of approximately RMB174.2 million for the Corresponding Period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of an interim dividend of approximately HKD238.9 million for the six months ended June 30, 2025, representing HKD0.51 per share (in cash).HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its unaudited consolidated interim results for the six months ended June 30, 2025 (the “Reporting Period”). During the Reporting Period, the Company sustained robust operations and realized a revenue of approximately RMB2,099.7 million, representing a YOY growth of approximately 133.8%. Profit attributable to Shareholders amounted to approximately RMB865.4 million, representing a YOY turnaround to profit from the net loss attributable to Shareholders of approximately RMB174.2 million in the Corresponding Period, and an increase of approximately RMB1,039.6 million in the Reporting Period. These fully demonstrate the effective strategy execution and high market adaptability of the Company.The Company places great emphasis on Shareholders returns. Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of an interim dividend of approximately HKD238.9 million for the six months ended June 30, 2025, representing HKD0.51 per share (in cash). Maintaining a prudent dividend policy not only reflects the strong profitability of our core business and our ample cash flows, but also highlights our strong sense of responsibility and commitment to Shareholders returns. Since the listing of the Company in 2023, the Company has made cash dividend payments for consecutive years with increasing dividend payout ratio. Notably, the dividend payout ratio reached 50.3% for 2024.Developing a dimensional product matrix for revenue diversificationLeveraging on the synergy and conversion of the products under our existing four main product lines, we further strengthened our core advantages in “intelligent algorithms + professional investment research + ecosystem services”, drove the transformation of our next-generation stock investing assistants from “feature-focused” to “experience-orientated”, and continued to improve our digital financial infrastructure, thereby facilitating the development of personalized and inclusive financial services.We consolidated the foundation of our large-amount software products and delivered our expertise in investment advisory services to ensure robust and strong performance of the core business. Empowered by AI technology, we fully delivered our expertise in investment advisory by newly launching 8 stock monitoring indicators and the “FinSphere SmartInvest” quantitative product that further strengthened our AI service capabilities. At the same time, we advanced the framework construction of our Stock Learning Machine through forming the three main matrices of “content, tool and trading” with focus on six core modules such as courses, live streaming and tools, to create a comprehensive learning platform. During the Reporting Period, It underwent 5 major version iterations and over 200 feature optimizations.In addition, we refined our small-amount series products to enhance our product strengths and operational capabilities and accelerate the platform development of our App. We built a Chief IP ecosystem integrating K-line chart analysis and expert insights,that enabled us to precisely distribute contents through a user tagging system. We upgraded our market information by enriching data such as capital flow trends, Hong Kong and US stocks, and launched new features of stock monitoring and portfolio watchlist. We optimized our information page with an infinite content feed, personalized recommendations, and improved visual hierarchy. Meanwhile, we also expanded multiple distribution channels including app stores, and refined our marketing strategies through data analysis. By sorting out the bottlenecks in registered users’ activation, we implemented tiered strategies to enhance utilization rates. Our homepage was dynamically optimized to enhance the attractiveness of its first screen. These measures accelerated the development of our App platform, broadened our user coverage and product exposure, increased the trustworthiness and stickiness of our App and created a closed loop of “content nurtures users and trust drives conversion”.Adhering to Artificial Intelligence + Investment Advisory strategy and refining our “1+N” investment research systemWith focus on the “buyer-side investment advisory” service, we vigorously developed “AI+” and further strengthened our “1+N” investment research system to fully penetrate our investment research into businesses and processes, so as to professionally support our customers in creating long-term value. We continued to make significant investment and effort in research and development. During the Reporting Period, we invested approximately RMB147 million in R&D activities. Meanwhile, as of the end of the Reporting Period, we had 139 software copyrights and patents on product features, big data, and AI, that represented an increase of 21 YOY.We actively explored the all-round empowerment of AI in the securities sector. We practiced “AI + Investment Advisory” providing a one-stop intelligent investment research platform which consolidates the core strengths of comprehensive stock analysis, multi-dimensional stock profiling, and diverse quantitative stock selection, and delivers professional investment research capabilities in an accessible, personalized, and empathetic manner that suits different types of investors. Meanwhile, considering compliance as our lifeline, we built an intelligent compliance and risk control platform covering the entire business process that creates a closed compliance loop of complete activity logging, data traceability, risk blocking, intelligent quality inspection and human-machine collaboration. During the Reporting Period, the cumulative number of behavioral monitoring tasks conducted by our “AI Monitoring Officer” increased by over approximately 77% as compared with 940 million in the Corresponding Period, and our “AI Inspection Officer” for content quality inspection assisted in nearly 2.2 million review tasks, reflecting that full coverage has been basically achieved.Based on our “1 research institute and N business lines” investment research system with our JF Financial Research Institute at the core, we continued to refine our underlying business competitiveness in securities investment advisory. Guided by the principle of “conducting higher-dimensional research and providing lower-dimensional services”, the institute is committed to developing a domestically leading and characteristically distinctive investment research service platform in China to provide long-term and steady, systematic, trustworthy and professional research services for investors. As of the end of the Reporting Period, the institute established a pyramid team structure consisting of 4 experts, 9 super-IPs and 128 professionals. It studied over 4,000 companies in over 20 industries.Refining traffic operation on MCNs with AI empowerment to build a high-quality traffic systemBy capitalizing on our refined traffic operations and realizing traffic reuse, we effectively expanded our business scale and improved our profit margins through optimization of operational efficiency. During the Reporting Period, using AIGC to optimize content production, we enhanced the production efficiency of premium contents. Moreover, using Douyin as our primary channel, we established a multi-platform layout with focus on Kuaishou, Xiaohongshu and Bilibili, to extend the boundaries of traffic operation scenarios. As of the end of the Reporting Period, the Company operated 994 MCN accounts on different internet platforms. These accounts attracted approximately 63.06 million followers, representing an increase of 17.47 million as compared with the Corresponding Period.At the same period, we actively practiced investor education for greater brand influence. We joined the Investor Education Alliance of China Fund and opened a Yinghua account to provide inclusive, systematic and differentiated investor education content for investors, contributing to the long-term development of stock investing theory. We exclusively sponsored Chinese Business Network’s live broadcast of the Berkshire Hathaway Annual Shareholders Meeting for the sixth consecutive year. Through “Buffett and Seven Lunches”, we helped investors build cognitive understanding of investing, and we specially organized a US study tour, bringing nearly a hundred investors to attend the meeting in person so that they could directly ask the stock god questions about value investing. This created a dialogue between the general investors and the iconic investor, aiming to provide them with more diverse and down-to-earth investment advice and forward-looking insights. We also attended “Financial Powerhouse”, a featured program of China Central Television, to provide deep explanation and analysis of the paradigm shift of the Company’s “AI + Investment Advisory” services empowered by fintech.Business outlookThe chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, Mr. Chen Wenbin said: "Consistently adhering to the concepts of rational investing, value investing and long-term investing, we insisted on adopting a customer-centric approach to develop a dimensional product system and continuously improve our services. Looking forward to future, we, as a next-generation stock investing assistant, will continue to strengthen our competitiveness, solidify our market leadership and strive to make investing and wealth management easier yet more professional, and enhance the happiness of investment and wealth management. "About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, stock learning machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2025 ACN Newswire via SeaPRwire.com.

West Palm Beach, FL, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has agreed to a multi-year partnership as the new title sponsor of The Palm Beaches Marathon. The U.S. Polo Assn. Palm Beaches Marathon, a race owned and managed by Ken Kennerly's K2 Sports Ventures, will be held in Downtown West Palm Beach, Florida, on December 13-14, 2025.USPA MarathonThis renowned marathon event is recognized for its beautiful views of the waterfront and palm-tree-lined streets and welcomes runners from across the country and around the world to the warmth of Florida during the cold winter months. It is also a qualifier for the legendary Boston Marathon."U.S. Polo Assn. is honored to be the Title Sponsor of The Palm Beaches Marathon, an iconic event that, like our brand, is deeply rooted in this vibrant community of Palm Beach County," said J. Michael Prince, President and CEO of USPA Global, the company that oversees the global, multi-billion-dollar U.S. Polo Assn. brand. "While our sport-inspired brand has a worldwide footprint in more than 190 countries, our heart and heritage are right here in The Palm Beaches, home to USPA Global, the United States Polo Association, and the USPA National Polo Center, the most prestigious polo destination in the world."The race weekend will include the 5K and 10K at 7:30 a.m. Saturday, December 13, followed by the featured Marathon, Half Marathon, and Marathon Relay on Sunday, December 14 at 6 a.m. Early registration is now open. Cost is $130 for the Marathon and $100 for the Half Marathon. The early registration fee for the 10K is $60, and $45 for the 5K. To register for The U.S. Polo Assn. Palm Beaches Marathon, visit palmbeachmarathon.com.A Health and Fitness Expo will coincide with race packet pickup on Friday, December 12, from 12 p.m. to 6 p.m. and Saturday, December 13, from 10 a.m. to 6 p.m. at the Meyer Amphitheatre, 104 Datura St., West Palm Beach. The Expo will feature the latest in health and fitness products and services, running apparel, and upcoming race information."We are excited to add a renowned global brand like U.S. Polo Assn. as the Title Sponsor of The Palm Beaches Marathon," Kennerly said. "This is a massive deal for the future of our race and its appeal to runners throughout the world. The Palm Beaches are a globally recognized blue-chip destination, and we are looking forward to continuing to grow the race not only in our community, but also on an international level."U.S. Polo Assn. brand products include apparel for men, women, and children, as well as accessories, luggage, watches, shoes, home furnishings, and more, with distribution across 190 countries through independent retail stores, department stores, U.S. Polo Assn. brand stores and e-commerce."Partnering with The Palm Beaches Marathon allows us to celebrate athletic excellence, community spirit, health and wellness, as well as the shared passion for sport that connects us locally and around the world. From the polo fields to the streets of Palm Beach, we are inspired by the athletes who give their all, and we look forward to sharing in the energy, camaraderie, and world-class competition that make The Palm Beaches Marathon truly special," Prince added.The race will support local charities, soon to be announced.WPBF 25, the Hearst-owned ABC Affiliate, will return as the Official Broadcast Station of the race and will provide extensive pre- and post-race coverage on all on-air and digital channels, as well as produce a live broadcast on Marathon race morning."WPBF 25 is thrilled to extend our partnership for a second year in a row as the Official Broadcast Station of the U.S. Polo Assn. Palm Beaches Marathon, reaffirming our commitment to help bring such a unique and exciting event like this to our community," said President and General Manager, Caroline Taplett. "Working together with our incredible partners, Ken Kennerly and the Marathon team, we are dedicated to promoting a more connected community, supporting local businesses, and inspiring participants, locally, nationally, and internationally to join us in beautiful South Florida for this one-of-a-kind experience."About U.S. Polo Assn.U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.About The U.S. Polo Assn. Palm Beaches MarathonThe U.S. Polo Assn. Palm Beaches Marathon is a premier winter running event held annually in West Palm Beach, which features a range of race distances designed for runners of all abilities, including a full marathon, half marathon, 10K, 5K, and a 4-person marathon relay. Highlighted by a 100% flat, USATF-certified course, the Marathon serves as a Boston Marathon qualifier. The scenic route allows runners to experience West Palm Beach's vibrant downtown as it winds along palm-lined Flagler Drive, past historic neighborhoods, and features sparkling waterfront views. The event also supports community and charity efforts. Visit palmbeachmarathon.com.Contact InformationStacey KovalskyU.S. Polo Assn.skovalsky@uspagl.com(954) 673-1331Gary FermanSpecialty Sports(954) 558-5203SOURCE: U.S. Polo Assn. Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights (Unaudited)(HKD Thousand)Six months ended 30 June20252024Revenue122,775135,347Gross Profit47,27748,767Profit Attributable to Owners of the Company8,17218,510Gross Profit Margin39%36%Basic Earnings per Share (HK cents)0.581.31HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com)  Dynasty Fine Wines Group Limited (“Dynasty” or the “Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its unaudited interim results for the six months ended 30 June 2025.In the first half of 2025, as the Group strengthened the effort for dry white market in coastal region and the new launch of white wine and sparkling wine products, the Group’s sales revenue of white wine products maintained a good momentum. But due to the impact of macroeconomy, fluctuations in consumer market in the PRC, as well as increase in marketing and promotion expenses, the Group's revenue for the first half of 2025 decreased by 9% to approximately HKD 123 million compared to the same period in 2024. Profit attributable to owners of the Company declined by 56% to approximately HKD 8.2 million year-on-year. Basic earnings per share were approximately HK0.58 cents per share. The overall gross profit margin increased to 39% from 36% for the corresponding period in 2024, mainly due to optimisation of product mix during the period.Sales of white wines products of the Group served as the Group’s primary revenue contributor during the period. Sales revenue of red and white wines products accounted for approximately 41% and 54% of the Group’s overall revenue respectively for the period. During the period, the gross profit margin of red wine products and white wine products were 38% and 39% respectively.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the period under review, the Group continued launching new products and carrying out product upgrade, that can better suit different palates, and cater for consumers with different spending power. That was done with an aim to invigorate the brand, as well as consolidating the image of Dynasty representative of domestic grape wine brand. The Group produced a wide range of more than 100 wine products under the “Dynasty” brand to meet the demands and preferences of different consumer groups mainly in the mass-market segments in the PRC wine market. During the period under review, the Group launched a new high-end product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. During this period, the Group continued strengthening cooperation with the Wine Association and carried out activities such as "Dragon University Tours" to further expand the brand's awareness and reputation among young people. Based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of "tea and wine fusion", has captured market attention with its unique craftsmanship. Based on white wine, this Tea-flavoured wine infuses the aromas of jasmine and Pu'er tea, creating a new oriental flavour within the traditional sparkling wine landscape. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Tianxia Winery won industry praise for their unique flavor and exquisite craftsmanship.Further to our commitment to core wine business in the PRC, the Group will develop new alcoholic beverages segments such as sauce-flavour baijiu, yellow wine and special yellow wine – Chenpi wine, through the newly set up joint venture companies, so as to diversify the sources of revenue. Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in Tianjin core-market with enthusiastic responses and will be further strategically promoted to other regions in the second half of the year. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness. For the yellow wine project, after planning, a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu will be under construction in the second half of 2025. Upon completion of the construction works, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry, and achieve a major strategic move towards high-quality development of the wine industry.Regarding E-commerce sales, the e-commerce team of the Group comprehensively operated online stores on traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based ecommerce platforms, including RED, Kuai and TikTok during the period under review. The Group’s autonomous brand communications could continue to gain the attention of mainstream consumer groups and demographic segments, and enhance effective market penetration of the Group’s products targeted at young consumers. The e-commerce team also actively cultivate e-commerce live broadcasting talents to further expand its sales channels so as to build up a new customer base.In addition, during the period under review, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea-flavoured Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series -Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to the second half of 2025, the Group will continue to focus on market and consumer demand and promote product quality through technological innovation. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to proactively develop new marketing prospects through innovation in product categories and consumption scenarios, and cross-industry co-operations in order to boost sales volume, which is in line with the country’s effort to promote domestic consumption and release the consumption growth potential.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul                                               Narro Communications                               E: farah@narrocomms.com                           Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing (dorzagliatin tablets), accelerated. The Company’s independent operational capabilities improved significantly. R&D progress advanced smoothly and the Company’s financial performance achieved breakthrough growth, laying a solid foundation for long-term sustainable development.Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance period.A real-world study (BLOOM) involving 80 centers and 2,000 patients with Type 2 diabetes conducted in China further demonstrated the broad applicability and safety of dorzagliatin.A registration application has been submitted in Hong Kong for Dorzagliatin 75mg (brand name: MYHOMSIS®), aiming to extend its presence across Greater China and Southeast Asia.Gross profit margin improved significantly, as production scale and operational efficiency continued to be optimized.“The first half of 2025 was a critical stage in Hua Medicine’s transformation and development. Following the full takeover of the commercialization of HuaTangNing, the Company achieved double-digit growth in sales and revenue through its independently established sales team, thereby validating the effectiveness of the new business model. We have also submitted a new drug application in Hong Kong, China, laying the foundation for dorzagliatin to expand from China to Southeast Asia and the global market,” said Dr. Li Chen, founder and CEO of Hua Medicin “Dorzagliatin has continued to demonstrate broad therapeutic potential in real-world studies, and new evidence has been found in basic research regarding diabetes remission, cognitive improvement, lipid improvement, and muscle gain, further consolidating Hua Medicine’s global leadership in GKA research and development and treatment. In the future, Hua Medicine will continue to focus on diabetes and the entire field of metabolic diseases, driving innovation through research and development and market expansion to bring the benefits of China's original innovative drugs to more patients worldwide.”   Business Highlights and Operational ProgressCommercialization transformation achieved remarkable results, with doubling of sales and profits.Effective from January 1, 2025, the Company terminated its exclusive promotion service agreement with Bayer and fully took over the commercialization of HuaTangNing (å''å ‚å®'®) in China. During the Reporting Period, with unit prices remaining consistent with the same period in 2024, sales of HuaTangNing reached 1,764,000 packs, a year-on-year increase of 108%. Net sales reached RMB217.4 million, a year-on-year increase of 112%. Leveraging strong commercial execution and continuously improving operational efficiency, the Company is moving toward profitability. Hua Medicine has successfully transitioned to a fully independent commercialization phase, confirming growing market demand and the efficient execution capabilities of its independent sales team.Sales of HuaTangNing continued to benefit from its inclusion in China’s National Reimbursement Drug List (NRDL), which took effect in January 2024. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption.Due to expanded production scale and improved cost efficiency, the Company's gross profit margin increased to 54.2%, higher than 46.5% in the same period last year.With sales revenue growing 112% year-on-year, the Company's sales expenses during the Reporting Period were RMB64.2 million for the six months ended June 30, 2025, growing only 5% compared to the same period last year. The composition of our selling expenses for the six months ended June 30, 2025 changed significantly from the same period in 2024 due to the Company incurring selling expenses directly as a result of assuming sole commercialization responsibilities for HuaTangNing in China, while no longer owing promotion expenses to the former commercialization partner. These figures also reflect a significant positive trend towards profitability and demonstrate our business strategy of optimizing profitability by controlling commercialization sales expenses of HuaTangNing and maximizing production efficiency, where our selling expenses in the first half of 2025 represent approximately 29.5% of total revenue whereas in the first half of 2024, our selling expenses represented approximately 59.5% of total revenue. After terminating the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB1,243.5 million and transitioned to self-driven growth. Hua Medicine achieved a pre-tax profit of RMB 1,183.9 million for the first half of the year, marking a key milestone of Hua Medicine towards sustainable profitability.As of June 30, 2025, the cash balance was RMB1,022.8 million, laying a solid foundation for the Company's future R&D and commercialization initiatives.Clinical research continues to deepen, with new evidence supporting treatment potentialHua Medicine is conducting multiple post-marketing studies to evaluate the long-term safety and effectiveness of dorzagliatin across diverse patient populations, both in monotherapy as well as in combination with other popular approved anti-diabetic drugs, such as GLP-1 receptor agonists, insulin, DPP-IV inhibitors and SGLT-2 inhibitors. These studies are generating new clinical insights into glucose control, cognitive outcomes, and potential for diabetes remission.A real-world study (BLOOM) is being conducted in 2,000 patients with Type 2 diabetes across 80 centers in China. BLOOM has already completed one-year follow-up in over 1,000 participants. In the real-world setting, BLOOM further demonstrates the broad applicability and safety of dorzagliatin. Patients receiving dorzagliatin in routine clinical practice present with a heterogeneous mix of comorbidities, including various cardiovascular and renal disorders and are managed with multiple concomitant medications. In addition to metformin, more than 60% of patients concurrently used SGLT-2 inhibitors, insulin, GLP-1 receptor agonists, or DPP-IV inhibitors and other anti-diabetic drugs with dorzagliatin. In monotherapy or in combination with the popular above-mentioned anti-diabetic drugs, dorzagliatin was generally well tolerated, and its safety profile remained consistent with previously established data.Hua Medicine presented new data at the 2025 American Diabetes Association (ADA) conference, reinforcing dorzagliatin’s potential as a disease-modifying therapy. Insights into the novel mechanism of action (MOA) of dorzagliatin as a therapeutic GKA were published in Diabetes.Research and Development Pipeline and Future OutlookThe company filed its application for registration of dorzagliatin 75mg in Hong Kong as MYHOMSIS®, aiming to extend its presence across Greater China and southeast Asia.We are continuing expansion on our product pipeline through development of fixed dose combination of metformin and dorzagliatin for patients who have failed to control blood glucose levels while using high dose metformin (daily dose>1500 mg). In the loose dose combination study-DAWN Trial, dorzagliatin add-on to metformin provided HbA1c reduction of greater than 1% and post meal glucose reduction of greater than 5 mmol/L. These desirable glycemic control levels coupled with a very safe 0.8% hypoglycemic rate would suggest strong potential demand for a branded oral anti-diabetic medication using a convenient fixed dose combination of dorzagliatin and metformin. The Pre-IND submission has been achieved in August 2025, and we are expected to initiate the bioequivalence study in early 2026.We are also advancing the combination of dorzagliatin with GLP-1RA, SGLT-2 inhibitors, insulin and DPP-IV inhibitors through combined effects in collecting real world evidence and proof of concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indications into other diseases in metabolic disorders, such as obesity and MASH.We continue to enhance our collaborations with leading international research institutions. A Phase I investigator-initiated trial supported by the Group and conducted at the University of Pennsylvania – designed to evaluate the efficacy and safety of dorzagliatin in patients with cystic fibrosis-related diabetes (CFRD) – has received clearance from the U.S. FDA.We will continue our engagement in diabetes prevention, opportunities in metabolic disorder related neurodegeneration disease and eventually find a new way to increase healthy life span and longevity in humans.We continue to invest in digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.As illustrated in our product pipeline chart, we will continue to advance our R&D efforts for both dorzagliatin and our 2nd generation GKA on our own as well as in collaboration with academic and strategic partners. We are working on the registration of dorzagliatin in Hong Kong and continue to seek partnerships in Southeast Asia and Belt and Road nations. In addition, we will continue our business development efforts on our 2nd generation GKA for the global markets based on the initial success of the Phase 1 single-ascending dose study in the United States and the initiation of our Phase 1 multiple ascending dose study planned for late 2025 or early 2026.Financial SummaryAs of June 30, 2025- Bank balances and cash amounted to approximately RMB 1,022.8 million.- Total revenue was approximately RMB217.4 million, representing a year-on-year increase of 112%. Sales of HuaTangNing (å''å ‚å®'®) reached 1,764,000 packs, representing a year-on-year increase of 108%.- Total gross profit was approximately RMB117.8 million, representing a year-on-year increase of 147%. Gross margin was approximately 54.2%, increased by approximately 7.7 percentage points, as compared with the six months ended June 30, 2024.- Total other income amounted to approximately RMB1,254.6 million , of which Bayer's one-time release of previously deferred income was RMB1,243,5 million.- Total expenditures were approximately RMB187.1 million, of which research and development expenditure was approximately RMB65.8 million.- Profit before tax was approximately RMB1,183.9 million, representing  approximately 932% for the six months ended June 30, 2025Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestors E-mail: ir@huamedicine.comMedia E-mail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK, hereinafter referred to as “Shoucheng Holdings”), Beijing Shoucheng Robotics Technology Industry Co., Ltd. (hereinafter referred to as “Shoucheng Robotics”), IAT Automobile Technology Co., Ltd. (300825.SZ, hereinafter referred to as “IAT”), and Beijing IATROBOT Technology Co., Ltd. (hereinafter referred to as “IATROBOT”) officially signed a strategic cooperation framework agreement.The four parties will leverage their respective strengths to carry out comprehensive cooperation in technological innovation, application deployment, industry chain collaboration, and talent cultivation within the robotics sector, jointly accelerating the development of new business models in the “Robotics + Automobiles” field.I. Industry Background: Robotics Entering the Acceleration Phase of Application DeploymentAt present, the global robotics industry is in a stage of rapid development, with national strategies and policies being introduced intensively. On August 26, the State Council officially released the Opinions of the State Council on Deeply Implementing the “AI+” Initiative (Guo Fa [2025] No. 11), which explicitly calls for promoting the extensive and in-depth integration of artificial intelligence with various industries and fields across the economy and society, and accelerating the formation of new models of intelligent economy and intelligent society characterized by human-machine collaboration, cross-industry integration, and co-creation.Under this national strategy, the robotics industry is shifting from “technological breakthroughs” to “application deployment.” Automobiles and robotics, as two highly complementary industries, are increasingly showing a trend of cross-sector integration. The cooperation between Shoucheng Holdings and IAT Group, under the dual drivers of favorable policy and strong market demand, will inject new momentum into robotics applications across key segments such as R&D, manufacturing, transportation, and mobility services.IAT is a leading enterprise in China’s automotive design field and the only independent automotive design company listed on the A-share market. The company provides full-process services ranging from complete vehicle R&D and design to core component manufacturing, while pursuing a globalization strategy of “technology + supply chain.” According to public information, IAT has served more than 80 clients and participated in the development of nearly 500 vehicle models. Its clients include major OEMs such as FAW, Dongfeng, BAIC, Geely, emerging EV brands, as well as joint-venture automakers. This highlights IAT’s strong OEM resources and delivery capabilities across the automotive value chain.At the same time, through its subsidiary — Beijing IATROBOT Technology Co., Ltd. — IAT has officially entered the robotics sector. IATROBOT is dedicated to building an integrated R&D, design, and simulation training platform, capable of supporting multi-scenario robotics development from simulation and testing to optimization. The company has already launched multiple R&D projects, including wheeled robots, underwater robots, drilling robots, and pet-care robots, demonstrating its potential in cross-scenario development and industry collaboration. The involvement of IATROBOT expands the scope of this cooperation beyond traditional automotive design, providing important support for the integration of robotics R&D, simulation, and automotive industrialization.By partnering with IAT and IATROBOT, Shoucheng will be able to embed robotics technologies deeply into the core stages of the automotive value chain, such as vehicle manufacturing, intelligent assembly, and production line testing. This will enable robots to truly enter the production line and accelerate industrial adoption. This strategic cooperation is not merely a technological connection — it leverages IAT’s extensive OEM client network to move robotics scenarios from “next-door demonstrations” directly into the “factory workshop,” bridging the crucial pathway between R&D validation and scaled industrial delivery.II. Key Areas of Cooperation: Balancing R&D Breakthroughs and Application DeploymentGuided by the State Council’s “AI+” Initiative, the four parties will anchor their collaboration on the full chain of “technology R&D — industrial application — ecosystem co-construction,” working together to drive industrial innovation. The cooperation will focus on the following areas to promote the deep integration of robotics and automobiles:(1) Technological Innovation and Joint R&DThe four parties will jointly build an integrated robotics R&D and simulation platform, drawing on the comprehensive R&D system of the automotive industry. The focus will be on achieving breakthroughs in key areas such as motion control, structural optimization, automotive-grade components, and large-scale manufacturing. Leveraging NVIDIA Isaac/Omniverse technology, the parties will co-develop an integrated simulation training platform that not only supports simulation of robotics applications in automotive R&D, manufacturing, and testing, but also enables cross-scenario simulations such as collaborative operations between autonomous driving vehicles and logistics robots.In addition, a mechanism for data and outcome sharing will be established: Shoucheng Holdings will provide operational data resources from transportation and mobility scenarios, while IAT will contribute expertise in automotive engineering and robotics R&D, together forming a complete closed loop spanning simulation — R&D — validation — production line application.(2) Priority Procurement and Synergy MechanismAcross R&D design, simulation training, complete machine and component supply, the four parties will adopt a priority procurement mechanism, under which signatories will be given preference as partners under equivalent conditions. Shoucheng Holdings and Shoucheng Robotics will focus on product promotion, distribution, and supporting services, while IAT and IATROBOT will concentrate on technology R&D, engineering validation, and customized whole-machine development.The parties will also work together to advance secondary development of robotic systems, ensuring optimal adaptation of robotics products to scenarios such as automotive production lines, intelligent assembly, and line testing. Through division of labor and collaborative mechanisms, a complementary cycle of product supply — technological innovation — application feedback will be established, accelerating the conversion of results and enhancing commercialization efficiency.(3) Talent DevelopmentLeveraging the research and industrial platforms of Shoucheng, IAT, and their partners, the four parties will jointly carry out technological problem-solving, simulation training, and application pilots, providing researchers and engineers with cross-industry, cross-scenario practical environments. Regular technical seminars and industry forums will be held, inviting experts and upstream and downstream enterprises to participate, thereby establishing a joint talent development mechanism. This initiative aims to cultivate a new generation of young researchers with both automotive engineering backgrounds and practical experience in robotics industrialization, laying a solid talent foundation for long-term growth.(4) Expanding Development HorizonsThe four parties will closely align with national strategies for “AI+” and robotics industry development, with a focus on scaling up “Robotics + Automobiles” applications in R&D, manufacturing, testing, and mobility services. Building on this foundation, the cooperation will gradually extend into broader fields such as smart transportation, intelligent manufacturing, healthcare, education, and public services, covering the design, R&D, production, testing, and commercialization of robots and core components. At the same time, by integrating capital and industry, the parties will drive coordinated upgrades across the value chain, ultimately forming a full-cycle closed loop from R&D validation to large-scale application. This will create a demonstrative “Robotics + Automobiles” application matrix, achieving mutual benefits and long-term value creation.III. Strategic Significance: Establishing a New Benchmark for Robotics ApplicationsThe greatest value of the robotics industry lies in real-world applications, and “Robotics + Automobiles” stands out as one of the most promising and high-potential application directions. From complete vehicle R&D to intelligent manufacturing, from traffic scheduling to smart mobility, robots will create tremendous value across the entire automotive value chain.Shoucheng Holdings, leveraging its capital platform, ecosystem resources, and industrial fund advantages, has invested in leading domestic enterprises such as Unitree Robotics, Galbot, Noetix Robotics, Galaxea-AI, and Booster Robotics, equipping it with the capability to integrate frontier technologies. Shoucheng Robotics has established collaborations with hundreds of high-quality upstream and downstream enterprises, making it one of the most comprehensive resource-linking platforms in China. IAT and IATROBOT, in turn, bring mature automotive engineering systems into robotics R&D and industrialization. Together, the combined strengths of both sides will form a complete pathway of “R&D — iteration — application — scale-up.”By joining forces with IAT, Shoucheng will further integrate its scenario resources and industrial ecosystem with IAT’s expertise in vehicle R&D, engineering capabilities, and industrialization experience. Over the next one to two years, the cooperation will focus on the deep integration of “Robotics + Automobiles,” taking the lead in demonstrating large-scale applications across vehicle R&D, production and manufacturing, smart transportation, and mobility services. This will accelerate the transition of robotics from laboratories to industrialization and large-scale deployment, creating a demonstrative “Robotics + Automobiles” application matrix. At the same time, the cooperation will also look to the international market, bringing Chinese solutions to the global stage, fostering new quality productivity, and generating long-term value for shareholders.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.